The FDA has issued warning letters to at least four peptide-related companies and one compounding pharmacy since January 2026, while a fifth pharmacy voluntarily recalled out-of-specification compounded products that included sermorelin and NAD+. The actions span the full supply chain — from bulk peptide distributors to licensed compounding pharmacies — and establish a clear enforcement pattern heading into fall 2026.
The Actions, Newest First
Peptide Partners LLC (August 24, 2026). The FDA cited Peptide Partners for unapproved new drug violations and misbranding. The letter is the most recent in a string of enforcement actions this year targeting distributors that sell peptides for use in compounding. (FDA warning letter)
Wholesale Peptide (June 17, 2026). A warning letter went to Wholesale Peptide approximately six weeks after the Ready Med action. (FDA warning letter)
Ready Med (June 8, 2026). A third letter issued around the same time. (FDA warning letter)
Olympia Pharmacy voluntary recall. Olympia Pharmacy issued a voluntary nationwide recall of seven compounded products found to be out-of-specification, including lots of sermorelin and NAD+. (FDA recall announcement)
GenoGenix LLC (January 20, 2026). This warning letter addressed NAD+ compounded with excessive bacterial endotoxins and stated that NAD+ does not appear on the FDA's 503B bulk substances list, making it ineligible for the exemptions that 503B outsourcing facilities use. (FDA warning letter)
Why the 503B Point Matters
Federal compounding law creates two tracks. A §503A pharmacy dispenses compounded medications based on individual patient-specific prescriptions from a licensed practitioner. A §503B outsourcing facility can produce larger batches without individual prescriptions — but only using substances on the FDA's approved bulk list.
The GenoGenix letter is a reminder that NAD+ does not currently appear on that 503B list. That does not make NAD+ compounding illegal; it means NAD+ can only be dispensed by a 503A pharmacy from a patient-specific prescription, not manufactured at scale by a 503B outsourcing facility. The distinction matters: 503A pharmacies prepare individual orders under tighter traceability than a high-volume outsourcing facility can maintain at scale.
Pallas Health addresses this directly on its peptide page, stating that "very few peptides qualify" for compounding under current rules — one of the clearer disclosures in this category. HealthRX also states plainly that its compounded medications are not FDA-reviewed and that NAD+ has limited human data.
What the Bacterial Endotoxin Finding Means
The contamination issue in the GenoGenix case — excessive bacterial endotoxins in a compounded NAD+ product — is a concrete safety signal, not a bureaucratic label. Endotoxins are cell-wall fragments from gram-negative bacteria. At high concentrations in an injectable preparation, they can cause fever, chills, rigors, and in serious cases contribute to systemic inflammatory responses. The FDA's own limits for intravenous preparations are measured in endotoxin units per milliliter and are kept deliberately low for this reason.
When evaluating any injectable longevity product — NAD+, sermorelin, or glutathione — the relevant question is not just "is this from a licensed pharmacy?" but "does this pharmacy test every batch before release, and can you see those results?" A clinician's assurance that testing happens is not the same as a certificate of analysis you can read. bmiMD states that "batch quality checks by licensed pharmacists" are performed; the certificate is described as available but is not published on the product page.
What This Does Not Tell Us
These five enforcement actions target distributors and pharmacies in the supply chain — not the telehealth clinics that write prescriptions and arrange dispensing. A clinic that prescribes through a fully compliant §503A pharmacy with proper batch testing is operating well outside any of these actions. The letters say nothing about any specific telehealth provider in our ranking.
What the pattern does confirm: the FDA's compounding enforcement desk is active in 2026, the supply chain above the clinic level carries real regulatory risk, and the quality of the compounding source matters as much as the telehealth platform a patient selects. When a clinic says "our pharmacy is licensed," the next question worth asking is which type of license, what batch testing protocols apply, and whether those results are available on request.
Sources: FDA warning letter to Peptide Partners LLC, Aug 24 2026; FDA warning letter to Wholesale Peptide, Jun 17 2026; FDA warning letter to Ready Med, Jun 8 2026; FDA warning letter to GenoGenix LLC, Jan 20 2026; Olympia Pharmacy voluntary recall.